Back to GetFilings.com
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2003
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from N/A to N/A
--- ---
Commission File No. 814-124
TECHNOLOGY FUNDING MEDICAL PARTNERS I, L.P.
-------------------------------------------
(Exact name of Registrant as specified in its charter)
Delaware 94-3166762
- ------------------------------- ---------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
1107 Investment Blvd., Suite 180
El Dorado Hills, California 95762
- --------------------------------------- --------
(Address of principal executive offices) (Zip Code)
(916) 941-1400
--------------------------------------------------
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act: Limited
Partnership Units
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes X No
--- ---
Indicate by check mark whether the registrant is an accelerated filer
(as defined in Rule 12B-2 of the Act). Yes No X
--- ---
No active market for the units of limited partnership interests
("Units") exists, and therefore the market value of such Units cannot be
determined.
Forward-Looking Statements
- --------------------------
The Private Securities Litigation Reform Act of 1995 (the Act) provides
a safe harbor for forward-looking statements made by or on behalf of the
Partnership. The Partnership and its representatives may from time to
time make written or oral statements that are "forward-looking",
including statements contained in this report and other filings with the
Securities and Exchange Commission, and reports to the Partnership's
shareholders and news releases. All statements that express
expectations, estimates, forecasts and projections are forward-looking
statements within the meaning of the Act. In addition, other written or
oral statements, which constitute forward-looking statements, may be
made by or on behalf of the Partnership. Words such as "expects",
"anticipates", "intends", "plans", "believes", "seeks", "estimates",
"projects", "forecasts", "may", "should", variations of such words and
similar expressions are intended to identify such forward-looking
statements. These statements are not guarantees of future performance
and involve certain risks, uncertainties and assumptions, which are
difficult to predict. Therefore, actual outcomes and results may differ
materially from what is expressed or forecasted in or suggested by such
forward-looking statements. The Partnership undertakes no obligation to
update publicly any forward-looking statements, whether as a result of
new information, future events or otherwise.
I. FINANCIAL INFORMATION
Item 1. Financial Statements
STATEMENTS OF NET ASSETS IN LIQUIDATION
- ---------------------------------------
(unaudited)
March 31, December 31,
2003 2002
------------ ------------
ASSETS
Equity investments (cost of
$1,249,035 and $1,965,144 at March
31, 2003, and December 31, 2002,
respectively) $ 274,037 $ 338,171
Cash and cash equivalents 1,555,380 1,825,441
Due from related parties 29,072 --
Other assets 341 683
--------- ---------
Total assets $1,858,830 $2,164,295
========= =========
LIABILITIES AND PARTNERS' CAPITAL
Accounts payable and accrued expenses $ 20,608 $ 24,216
Due to related parties -- 139,308
--------- ---------
Total liabilities 20,608 163,524
Commitments and contingencies (See Note 7)
Partners' capital
(79,716 Limited Partner Units
outstanding) 1,848,374 2,009,298
General Partners (10,152) (8,527)
--------- ---------
Total partners' capital 1,838,222 2,000,771
--------- ---------
Total liabilities and
partners' capital $1,858,830 $2,164,295
========= =========
The accompanying notes are an integral part of these financial
statements.
STATEMENTS OF INVESTMENTS IN LIQUDATION
- ---------------------------------------
Principal
amount or March 31, 2003 December 31, 2002
Industry shares at ----------------- -----------------
(1) Investment March 31, Cost Fair Cost Fair
Company Position Date 2003 Basis Value Basis Value
- ------------- -------- ------ ------------ ----- ----- ----- -----
Equity Investments
- ------------------
Medical/Biotechnology
- ---------------------
0.0% and 1.0% at March 31, 2003, and December 31, 2002, respectively
- --------------------------------------------------------------------
Acusphere, Inc. Preferred 1995-
(a) shares 1997 340,635 $ 706,251 $ 0 $ 706,251 $ 0
Prolinx, Inc. Preferred
(a) (b) shares 2001 -- -- -- 27,355 2,733
Prolinx, Inc. Common 1995-
(a) (b) shares 1998 -- -- -- 688,461 17,768
Prolinx, Inc. Preferred
(a) (b) share
warrants
at $.90;
expiring
2010 2001 -- -- -- 293 0
--------- --------- --------- ---------
706,251 0 1,422,360 20,501
--------- --------- --------- ---------
STATEMENTS OF INVESTMENTS IN LIQUIDATION (continued)
- ---------------------------------------------------
Medical/Diagnostic Equipment
- ----------------------------
14.6% and 14.6% at March 31, 2003, and December 31, 2002, respectively
- ----------------------------------------------------------------------
LifeCell Common 1996-
Corporation shares 2001 103,877 247,500 269,037 247,500 312,670
--------- --------- --------- ---------
247,500 269,037 247,500 312,670
--------- --------- --------- ---------
Pharmaceuticals
- ---------------
0.0% and 0.0% at March 31, 2003, and December 31, 2002, respectively
- --------------------------------------------------------------------
Periodontix, Preferred 1993-
Inc. (a) shares 1996 167,000 234,000 0 234,000 0
--------- --------- --------- ---------
234,000 0 234,000 0
--------- --------- --------- ---------
Environmental
- -------------
0.0% and 0.0% at March 31, 2003, and December 31, 2002, respectively
- --------------------------------------------------------------------
Triangle
Biomedical
Sciences, Common
Inc. (a) shares 1999 366 10,248 0 10,248 0
STATEMENTS OF INVESTMENTS IN LIQUIDATION (continued)
- ---------------------------------------------------
Triangle Common
Biomedical share
Sciences, warrant
Inc. (a) at $28.00;
expiring
2009 1999 366 366 0 366 0
--------- --------- --------- ---------
10,614 0 10,614 0
--------- --------- --------- ---------
Venture Capital Limited Partnership Investments
- -----------------------------------------------
0.3% and 0.2% at March 31, 2003, and December 31, 2002, respectively
- --------------------------------------------------------------------
Medical Science Limited
Partners II, L.P. Partnership
(a) interests various $250,000 50,670 5,000 50,670 5,000
--------- --------- --------- ---------
50,670 5,000 50,670 5,000
--------- --------- --------- ---------
Total equity investments - 14.9% and 15.8% at
March 31, 2003, and December 31, 2002,
respectively $1,249,035 $ 274,037 $1,965,144 $ 338,171
========= ========= ========= =========
STATEMENTS OF INVESTMENTS IN LIQUIDATION (continued)
- ---------------------------------------------------
Legend and footnotes:
-- No investment held at end of period.
0 Investment active with a carrying value or fair value of zero.
(a) Equity security acquired in a private placement transaction; resale may be subject to certain
selling restrictions.
(b) Portfolio company is an affiliate of the Partnership; resale may be subject to certain selling
restrictions.
(1) Represents the total fair value of a particular industry segment as a percentage of partners'
capital at March 31, 2003, and December 31, 2002.
The accompanying notes are an integral part of these financial statements.
STATEMENTS OF CHANGES IN NET ASSETS IN LIQUIDATION (unaudited)
- -------------------------------------------------------------
For the Three
Months Ended March 31,
-----------------------
2003 2002
---- ----
Investment income:
Interest income $ 4,564 $ 8,728
------- -------
Total investment income 4,564 8,728
Investment expenses:
Management fees 32,275 35,684
Individual General Partners'
compensation 7,500 9,705
Administrative and investor
services 31,147 67,496
Investment operations 13,163 14,483
Professional fees 14,549 15,401
Computer services 4,345 9,665
------- -------
Total investment expenses 102,979 152,434
------- -------
Net investment loss (98,415) (143,706)
------- -------
Net realized loss from write-off
of equity investments (716,109) --
------- -------
Net decrease in unrealized depreciation
of equity investments 651,975 128,404
------- -------
Net decrease in partners'
capital resulting from operations $(162,549) $(15,302)
======= =======
Net decrease in partners' capital
resulting from operations per Unit $ (2.02) $ (0.19)
======= =========
The accompanying notes are an integral part of these financial statements.
STATEMENTS OF CHANGES IN CASH FLOWS (unaudited)
- ----------------------------------------------
For the Three Months Ended March 31,
------------------------------------
2003 2002
------ ------
Net decrease in partners'
capital resulting from operations $ (162,549) $ (15,302)
Adjustments to reconcile net decrease
in partners' capital resulting
from operations to net cash used by
operating activities:
Net decrease in unrealized depreciation
of equity investments (651,975) (128,404)
Realized loss from write-off of
equity investments 716,109 --
Decrease in accounts payable
and accrued expenses (3,608) (11,110)
Increase in due from related
parties (168,380) (28,911)
Other changes, net 342 417
--------- ---------
Net cash used by operating activities (270,061) (183,310)
--------- ---------
Net decrease in cash and cash equivalents (270,061) (183,310)
Cash and cash equivalents at beginning
of year 1,825,441 2,378,800
--------- ---------
Cash and cash equivalents at March 31 $1,555,380 $2,195,490
========= =========
The accompanying notes are an integral part of these financial statements.
NOTES TO FINANCIAL STATEMENTS (unaudited)
- ----------------------------------------
1. Interim Financial Statements
----------------------------
The accompanying unaudited financial statements included herein have
been prepared in accordance with the requirements of Form 10-Q and,
therefore, do not include all information and footnotes, which would be
presented, were such financial statements prepared in accordance with
generally accepted accounting principles in the United States of
America. These statements should be read in conjunction with the Annual
Report on Form 10-K for the year ended December 31, 2002. In the opinion
of the Managing General Partners, the accompanying interim financial
statements reflect all adjustments necessary for the fair presentation
of the financial position, results of operations, and cash flows for the
interim periods presented. Allocation of income and loss to Limited and
General Partners is based on cumulative income and loss. Adjustments,
if any, are reflected in the current quarter balances. The results of
operations for such interim periods are not necessarily indicative of
results of operations to be expected for the full year.
2. Termination and Liquidation of the Partnership
----------------------------------------------
The Partnership term expired on December 31, 2002, per the Partnership
Agreement, and the Independent General Partners elected not to extend
the term as provided in the Partnership Agreement. In December 2002,
the Managing General Partners adopted a plan of liquidation. In
anticipation of the liquidation and dissolution, the Individual General
Partners, in March 2002, approved the retention of an independent third
party to value the Partnership's private holding and subsequently
engaged the third party to seek buyers for those investments. One of
those holdings was sold prior to December 31, 2002. Based upon the
results of the independent third party's actions, the Managing General
Partners determined that the fair value of the Partnership's investments
in portfolio companies totaled $338,171. The Individual General
Partners, acting as Trustee for the Partnership, have proceeded with
liquidating the remaining assets of the Partnership. In March 2003, the
Individual General Partners received a third-party bid of $5,000 for the
Partnership's holdings in Medical Science Partners II, L.P. The
Managing General Partners reduced the fair value as of December 31,
2002, of Medical Science Partners II to reflect the current market
value. An affiliated partnership has also expressed an interest in
purchasing the Medical Science Partners II assets. The Individual
General Partners approved a motion at their March 14, 2003, regular
meeting to accept the highest offer received, even if it is from an
affiliated entity, pending approval from the Securities and Exchange
Commission and the Limited Partners. As of March 31, 2003, the
Partnership's $716,109 investment in Prolinx, Inc. was written off. It
is possible there will be no willing buyers for the remaining assets.
The Liquidating Trustee will consider a number of options including
abandonment of the remaining assets or distribution to the Limited
Partners.
3. Provision for Income Taxes
--------------------------
No provision for income taxes has been made by the Partnership, as the
Partnership is not directly subject to taxation. The partners are to
report their respective shares of Partnership income or loss on their
individual tax returns.
The accompanying financial statements are prepared using accounting
principles generally accepted in the United States of America, which may
not equate to tax accounting. The cost of investments on a tax basis at
March 31, 2003, and December 31, 2002, was $1,249,040 and $2,131,918,
respectively. At March 31, 2003, and December 31, 2002, gross
unrealized appreciation and depreciation on investments based on cost
for federal income tax purposes were as follows:
March 31, December 31,
2003 2002
---------- ------------
Unrealized appreciation $ 21,537 $ 65,170
Unrealized depreciation (996,536) (1,858,917)
------- ---------
Net unrealized depreciation $(974,999) $(1,793,747)
======= =========
4. Related Party Transactions
--------------------------
Related party costs are included in investment expenses shown on the
Statements of Changes in Net Assets in Liquidation. Related party costs
for the three months ended March 31, 2003 and 2002, were as follows:
2003 2002
------ ------
Management fees $32,275 $35,684
Individual General Partners' compensation 7,500 9,705
Reimbursable operating expenses 32,313 72,274
Management fees are equal to 2 percent of the total Limited Partner
capital contributions for the first year of Partnership operations
through the sixth year. Beginning in the seventh year (May 2001),
management fees declined by 10 percent per year from the initial 2
percent. Management fees compensate the Managing General Partners
solely for general partner overhead (as defined in the Partnership
Agreement) incurred in supervising the operation and management of the
Partnership and the Partnership's investments. Management fees due to
the Managing General Partners were $10,758 at March 31, 2003, and
December 31, 2002, respectively, and were netted against due from
related parties at March 31, 2003, and included in due to related
parties at December 31, 2002.
The Partnership reimburses the Managing General Partners for certain
operating expenses incurred in connection with the business of the
Partnership. Reimbursable operating expenses paid by the Managing
General Partners include expenses (other than organizational and
offering expenses and general partner overhead) such as administrative
and investor services, investment operations, and computer services.
Certain reimbursable expenses have been accrued based upon interim
estimates prepared by the Managing General Partners and are adjusted to
actual costs periodically. Amounts due from related parties for such
expenses were $39,830 at March 31, 2003. Amounts due to related parties
were $128,550 at December 31, 2002.
Officers of the Managing General Partners occasionally receive stock
options as compensation for serving on the Boards of Directors of
portfolio companies. It is the Managing General Partners' policy that
all such compensation be transferred to the investing partnerships. If
the options are non-transferable, they are not recorded as an asset of
the Partnership. Any profit from the exercise of such options will be
transferred if and when the options are exercised and the underlying
stock is sold by the officers. Any such profit is allocated amongst the
Partnership and affiliated partnerships based on their proportionate
investments in the portfolio company. At March 31, 2003, the
Partnership and affiliated partnerships had an indirect interest in non-
transferable Endocare, Inc. options with a fair value of $0.
Retention bonuses were offered to and accepted by key employees of the
Managing General Partners in late 2002. The expense for these bonuses,
approved by the Individual General Partners during the September 2002
Independent General Partner meeting, was $48,690 and was paid and fully
expensed in 2002. The bonuses, incremented by annual salary increases,
will be paid to those individuals who are still full-time employees of
the Managing General Partners in April 2007. Upon the resignation of
personnel, no adjustment to the retention bonus amount previously paid
by the Partnership to the Managing General Partners shall occur until a
replacement person is hired.
5. Equity Investments
------------------
All investments are valued at fair value as determined in good faith by
the Managing General Partners.
Marketable Equity Securities
- ----------------------------
Marketable equity securities had aggregate costs of $247,500 at March
31, 2003, and December 31, 2002, and aggregate fair values of $269,037
and $312,670 at March 31, 2003, and December 31, 2002, respectively.
The net unrealized gain at March 31, 2003, included gross gains of
$21,537. The gross gains at December 31, 2002, were $65,170.
Restricted Securities
- ---------------------
At March 31, 2003, and December 31, 2002, restricted securities had
aggregate costs of $1,001,535 and $1,717,644, respectively, and
aggregate fair values of $5,000 and $25,501, respectively, representing
0.3 percent and 1.2 percent of the net assets of the Partnership,
respectively.
Significant purchases, sales and write-offs of equity investments during
the quarter ended March 31, 2003, are as follows:
Prolinx, Inc.
- -------------
In March 2003, the Partnership wrote off its entire investment of
$716,109 in Prolinx, Inc. The company filed for Chapter 7 bankruptcy on
March 27, 2003. There is no anticipated recovery for the shareholders.
Other Equity Investments
- ------------------------
Other significant changes reflected in the Statements of Investments in
Liquidation relate to market value fluctuations for publicly traded
portfolio companies or changes in the fair value of private companies as
determined in accordance with the policy described in Note 1 to the
financial statements included in the Partnership's December 31, 2002,
Form 10-K.
6. Cash and Cash Equivalents
-------------------------
Cash and cash equivalents at March 31, 2003, and December 31, 2002,
consisted of:
2003 2002
------ ------
Demand accounts $ 66,776 $ 71,400
Money market accounts 1,488,604 1,754,041
--------- ---------
Total $1,555,380 $1,825,441
========= =========
7. Commitments and Contingencies
-----------------------------
From time to time the Partnership becomes a party to financial
instruments with off-balance-sheet risk in the normal course of its
business. Generally, these instruments are commitments for future
equity investment fundings, equipment financing commitments, or accounts
receivable lines of credit that are outstanding but not currently fully
utilized by a borrowing company. As they do not represent current
outstanding balances, these unfunded commitments are properly not
recognized in the financial statements. At March 31, 2003, there were
no unfunded investment commitments to portfolio companies and venture
capital limited partnerships.
From time to time, the Partnership is subject to routine litigation
incidental to the business of the Partnership. Although there can be no
assurances as to the ultimate disposition of these matters and the
proceeding disclosed above, it is the opinion of the Managing General
Partners, based upon the information available at this time, that the
expected outcome of these matters, individually or in the aggregate,
will not have a material adverse effect on the results of operations and
financial condition of the Partnership.
8. Financial Highlights
--------------------
For The Three Months Ended March 31,
-----------------------------------
2003 2002
------ ------
(all amounts on a per Unit basis)
Net asset value,
beginning of period $24.95 $50.34
(Loss) income from investment
operations:
Net investment loss (1.22) (1.78)
Net realized and unrealized
gain (loss) on investments (0.80) 1.59
------ ------
Total from investment
operations (2.02) (0.19)
------ ------
Net asset value, end of period $22.93 $50.15
====== ======
Total return (8.09)% (0.38)%
Ratios to average net assets:
Net investment loss (5.10)% (3.55)%
Expenses 5.40% 3.81%
Pursuant to the Partnership Agreement, net profit shall be allocated
first to those Partners with deficit capital account balances until such
deficits have been eliminated. The net asset values shown above assume
the Partnership is in liquidation and capital has been contributed by
the General Partners equal to the amount of deficit capital after
liquidation at March 31, 2003. As of March 31, 2003, the General
Partners have a negative capital balance of $10,152. Net asset value
has been calculated in accordance with this provision of the Partnership
Agreement.
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations
The Partnership term expired on December 31, 2002, per the Partnership
Agreement, and the Independent General Partners elected not to extend
the term as provided in the Partnership Agreement. In December 2002,
the Managing General Partners adopted a plan of liquidation. In
anticipation of the liquidation and dissolution, the Individual General
Partners, in March 2002, approved the retention of an independent third
party to value the Partnership's private holding and subsequently
engaged the third party to seek buyers for those investments. One of
those holdings was sold prior to December 31, 2002. Based upon the
results of the independent third party's actions, the Managing General
Partners determined that the fair value of the Partnership's investments
in portfolio companies totaled $338,171. The Individual General
Partners, acting as Trustee for the Partnership, have proceeded with
liquidating the remaining assets of the Partnership. In March 2003, the
Individual General Partners received a third-party bid of $5,000 for the
Partnership's holdings in Medical Science Partners II, L.P. The
Managing General Partners reduced the fair value as December 31, 2002,
of Medical Science Partners II to reflect the current market value. An
affiliated partnership has also expressed an interest in purchasing the
Medical Science Partners II assets. The Individual General Partners
approved a motion at their March 14, 2003, regular meeting to accept the
highest offer received, even if it is from an affiliated entity, pending
approval from the Securities and Exchange Commission and the Limited
Partners. As of March 31, 2003, the Partnership's $716,109 investment
in Prolinx, Inc. was written off. It is possible there will be no
willing buyers for the remaining assets. The Liquidating Trustee will
consider a number of options including abandonment of the remaining
assets or distribution to the Limited Partners.
Liquidity and Capital Resources
- -------------------------------
The Partnership operates as a business development company under the
Investment Company Act of 1940 and makes venture capital investments in
new and developing companies. The Partnership's financial condition is
dependent upon the success of the portfolio companies. There is no
ready market for many of the Partnership's investments. It is possible
that some of its venture capital investments may be a complete loss or
may be unprofitable and that others will appear likely to become
successful, but may never realize their potential. The valuation of the
Partnership's investments in securities for which there are no available
market quotes is subject to the estimate of the Managing General
Partners in accordance with the valuation guidance described in Note 1
to the financial statements included in the Partnership's December 31,
2002 Form 10-K. In the absence of readily obtainable market values, the
estimated fair value of the Partnership's investments may differ
significantly from the values that would have been used had a ready
market existed.
During the three months ended March 31, 2003, net cash used by operating
activities totaled $270,061. The Partnership paid management fees of
$32,275 to the Managing General Partners and reimbursed related parties
for investment expenses of $200,693. In addition, $7,500 was paid to
the Individual General Partners as compensation for their services. The
Partnership paid other investment expenses of $34,157. Interest income
of $4,564 was received.
Cash and cash equivalents at March 31, 2003, were $1,555,380. Future
proceeds from investment sales and operating cash reserves are expected
to be adequate to fund Partnership operations through the next twelve
months.
Results of Operations
- ---------------------
Current quarter compared to corresponding quarter in the preceding year
- -----------------------------------------------------------------------
Net decrease in partners' capital resulting from operations was $162,549
for the three months ended March 31, 2003, compared to a net decrease in
partners' capital resulting from operations of $15,302 for the same
period in 2002.
During the quarter ended March 31, 2003, the Partnership wrote off its
entire investment in Prolinx, Inc. The company filed for bankruptcy in
March 2003, and there is no anticipated recovery for the shareholders.
There were no write-offs during the same period in 2002.
Net unrealized depreciation on equity investments was $974,998 and
$1,626,973 at March 31, 2003, and December 31, 2002, respectively.
During the quarter ended March 31, 2003, the Partnership recorded a
decrease in net unrealized depreciation on equity investments of
$651,975 compared to a decrease in unrealized depreciation of $128,404
during the quarter ended March 31, 2002. The change in 2003 was
primarily attributable to the write-off of the Partnership's entire
investment in Prolinx, Inc. The change in 2002 was primarily
attributable to an increase in the publicly traded price of LifeCell
Corporation.
Total investment expenses were $102,979 for the quarter ended March 31,
2003, compared to $152,434 for the same period in 2002. The decrease is
attributable to decreased administrative and investor services activity.
Given the inherent risk associated with the business of the Partnership,
the future performance of the portfolio company investments may
significantly impact future operations.
Item 4. Procedures and Controls
The undersigned is responsible for establishing and maintaining
disclosure controls and procedures for Technology Funding Medical
Partners I, L.P. Such officer has concluded (based upon his evaluation
of these controls and procedures as of a date within 90 days of the
filing of this report) that Technology Funding Medical Partners I,
L.P.'s disclosure controls and procedures are effective to ensure that
information required to be disclosed by Technology Funding Medical
Partners I, L.P. in this report is accumulated and communicated to
Technology Funding Medical Partners I, L.P.'s management, including its
principal executive officers as appropriate, to allow timely decisions
regarding required disclosure.
The certifying officer also has indicated that there were no significant
changes in Technology Funding Partners III, L.P.'s internal controls or
other factors that could significantly affect such controls subsequent
to the date of their evaluation other than changes needed to maintain
adequate separation of duties and responsibilities of personnel in the
ordinary course of business, and there were no corrective actions with
regard to significant deficiencies and material weaknesses.
CERTIFICATION
-------------
I, Charles R. Kokesh, President, Chief Executive Officer, Chief
Financial Officer and Chairman of Technology Funding Inc. and Managing
General Partner of Technology Funding Limited, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Technology
Funding Medical Partners I, L.P.;
2. Based on my knowledge, this quarterly report does not contain any
untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to
the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all
material respects the financial condition, results of operations and
cash flows of the registrant as of, and for, the periods presented in
this quarterly report;
4. I am responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for
the registrant and I have:
a) designed such disclosure controls and procedures to ensure that
material information relating to the registrant is made known to me by
others within the entity, particularly during the period in which this
quarterly report is being prepared;
b) evaluated the effectiveness of the registrant's disclosure controls
and procedures as of a date within 90 days prior to the filing date of
this quarterly report (the Evaluation Date); and
c) presented in this quarterly report my conclusions about the
effectiveness of the disclosure controls and procedures based on my
evaluation as of the Evaluation Date;
5. I have disclosed, based on my most recent evaluation, to the
registrant's auditors and the audit committee of registrant's board of
directors (or persons performing the equivalent function):
a) all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to
record, process, summarize and report financial data and have identified
for the registrant's auditors any material weaknesses in internal
controls; and
b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal
controls; and
6. I have indicated in this quarterly report whether or not there were
significant changes in internal controls or in other factors that could
significantly affect internal controls subsequent to the date of my most
recent evaluation, including any corrective actions with regard to
significant deficiencies and material weaknesses.
Date: May 15, 2003 By: /s/Charles R. Kokesh
--------------------------------
Charles R. Kokesh
President, Chief Executive
Officer, Chief Financial
Officer and Chairman of
Technology Funding Inc. and
Managing General Partner of
Technology Funding Limited
II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K
(a) No reports on Form 8-K were filed by the Partnership during the
Quarter ended March 31, 2003.
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.
TECHNOLOGY FUNDING MEDICAL PARTNERS I, L.P.
By: TECHNOLOGY FUNDING INC.
TECHNOLOGY FUNDING LTD.
Managing General Partners
Date: May 15, 2003 By: /s/Charles R. Kokesh
---------------------
Charles R. Kokesh
President, Chief Executive Officer,
Chief Financial Officer and
Chairman of Technology Funding Inc.
and Managing General Partner of
Technology Funding Ltd.
CERTIFICATION
-------------
In connection with the Technology Funding Medical Partners I, L.P. (the
Partnership) Quarterly Report on Form 10-Q for the period ending March
31, 2003, as filed with the Securities and Exchange Commission (the
Report), I Charles, R. Kokesh, President, Chief Executive Officer, Chief
Financial Officer and Chairman of Technology Funding Inc. and Managing
General Partner of Technology Funding Limited, certify, pursuant to 18
U.S.C. Section 1350, as added Section 906 of the Sarbanes-Oxley Act of
2002, that:
1. The Report fully complies with the requirements of Section 15(d)
of the Securities Exchange Act of 1934; and
2. To my knowledge, the information contained in the Report fairly
presents, in all material respects, the financial condition and
results of operations of the Partnership as of and for the period
covered by the Report.
Date: May 15, 2003 By: /s/Charles R. Kokesh
------------------------------
Charles R. Kokesh
President, Chief Executive
Officer, Chief Financial
Officer and Chairman of
Technology Funding Inc. and
Managing General Partner of
Technology Funding Limited